Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives

Highlights • Induction chemotherapy in non-surgical protocols included a small proportion of patients with oral cavity cancers. • Induction chemotherapy with three drugs (taxane plus PF) followed by (chemo)radiotherapy improved overall survival compared to induction chemotherapy with two drugs (PF)...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2015-12, Vol.51 (12), p.1069-1075
Main Authors: Marta, Gustavo Nader, William, William N, Feher, Olavo, Carvalho, André Lopes, Kowalski, Luiz Paulo
Format: Article
Language:English
Subjects:
Clinical Trials as Topic
Hematology, Oncology and Palliative Medicine
Humans
Induction chemotherapy
Induction Chemotherapy - methods
Laryngeal Neoplasms - drug therapy
Mouth Neoplasms - drug therapy
Neoplasms
Oral cavity
Oropharyngeal Neoplasms - drug therapy
Otolaryngology
Pharyngeal Neoplasms - drug therapy
Radiotherapy
Surgery
Treatment
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Induction chemotherapy in non-surgical protocols included a small proportion of patients with oral cavity cancers. • Induction chemotherapy with three drugs (taxane plus PF) followed by (chemo)radiotherapy improved overall survival compared to induction chemotherapy with two drugs (PF) followed by (chemo)radiotherapy. • In general, induction chemotherapy followed by chemoradiotherapy compared to chemoradiotherapy upfront has similar clinical outcomes (overall survival). • No overall survival benefit was observed in oral cavity cancer patients treated with induction chemotherapy followed by surgery with or without postoperative radiotherapy compared to surgery upfront with or without postoperative radiotherapy, in randomized, phase 3 clinical trials. • Upcoming studies must focus on identifying biomarker features associated with response to induction chemotherapy and improved survival.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2015.10.009